Investing.com - Financial Markets Worldwide

Aim ImmunoTech CEO Thomas K Equels buys $2,583 in common stock

Published 07/04/2025, 20:46
Aim ImmunoTech CEO Thomas K Equels buys $2,583 in common stock
AIMID
6.87%

In a recent transaction, Thomas K. Equels, CEO and President of AIM ImmunoTech Inc. (NYSE:AIM), purchased 41,000 shares of the company's common stock. The transaction comes as the stock has seen a significant decline, down over 20% year-to-date, according to InvestingPro data. The shares were acquired at a price of $0.063 each, totaling approximately $2,583. Following this transaction, Equels holds 1,899,029 shares directly in the $91.8 million market cap company. This activity was reported in a Form 4 filing submitted to the Securities and Exchange Commission, highlighting Equels' continued investment in the company despite AIM's current Fair Value indicating overvaluation. InvestingPro analysis reveals 13 additional key insights about AIM's financial health, which is currently rated as FAIR.

In other recent news, AIM ImmunoTech Inc. has announced that its common stock has started trading on the Pink Open Market under the new ticker symbol AIMI. This move follows the company's notice of potential delisting from the NYSE American exchange due to low stock prices, prompting AIM ImmunoTech to appeal the decision. The company has scheduled a Special Meeting to discuss a possible reverse stock split, as indicated in their Definitive Proxy Statement. AIM ImmunoTech's main investigational drug, Ampligen®, continues to undergo clinical trials for various diseases, although approval is not guaranteed. Investors are advised to review the company's recent filings with the SEC for further details on these developments. Meanwhile, AIM ImmunoTech has highlighted the risks and uncertainties inherent in drug development, urging caution among investors. The firm has also stated that it does not plan to update any forward-looking statements after their initial release. These recent developments are crucial for investors to consider as they evaluate AIM ImmunoTech's strategic direction.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.